
Poster Review for Clinical Studies

- The long term results of intracranial AVM treated by Proton Stereotactic Radiosurgery by *Daniel Kim, MD*
- Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-Term Outcome Based on Conditional Disease-Free Probability by Yuhree Kim, MD
- Pre-transplant HbA1c Predicts Post-transplant Diabetes Mellitus among Kidney Transplant Recipients
 by Jung-Im Shin, MD
- Quality measures that focus on patient and family engagement in oncology by *Song Kyungmin, MD*

Cerebral Arterio-Venous Malformation

Cerebral AVM: Tangle of abnormal blood vessels connecting arteries and veins in the Brain.






Cerebral Arterio-Venous Malformation

- Rare- affect less than 1 percent of the population
- The cause of AVMs is not clear -most people are born with them, but they can occasionally form later in life.
- They are rarely passed down among families genetically
- Mostly asymptomstic, some have headache or seizures. AVMs are commonly found after a brain scan for another health issue or after the rupture and cause bleeding in the brain (hemorrhage) mortality rate of 40 %, 66 % of survivors suffer permanent neurologic deficits.
- Rate of spontaneous rupture: 2 % / year
- Prevention of Rupture is important

Cerebral Arterio-Venous Malformation Imaging findings




Cerebral Arterio-Venous Malformation Treatments

Microsurgical Resection: Immediate and Successful but risky for Large AVM or AVMs located in eloquent area

 Stereotactic Radiosurgery: Mostly successful (> 80 % Obliteration Rate for small AVM, < 3 cm diameter). Takes 2 – 5 yrs for the obliteration after treament

Endovascular Embolization:Reduce the size of AVM but does not eliminate AVM by itself. Usually used in conjunction with Surgery or Radiosurgery

Cerebral Arterio-Venous Malformation Radiosurgery



Cerebral Arterio-Venous Malformation Radiosurgery: Findings from this study

- 248 Patients with AVM treated by Proton Radiosurgery
- 10 year Obliteration Rate: 91 %
- Post-treatement 5 year hemorrhage rate: 7%
- Size (median 3.5 cc, maximum 28 cc) and Location of AVM (23% deep, critical locations)
- Dose prescription (most common 15 Gy)
- Higher obliteration rates for Smaller target volume and Higher prescribed dose
- Future study: Comparison with Gamma knife Radiosurgery

Cancer Statistics

 "There are three kinds of lies: lies, damned lies and statistics." Disraeli -Mark Twain

"In this world nothing can be said to be certain, except death and taxes." Benjamin Franklin

Cancer Statistics

- Overall Survival (OS): 3, 5, 10, 15 years Disease Free Survival (DFS) Disease Specific Survival (DSS) Biochemical disease free Survival (BDFS) Local Control (LC) Toxicity Profile
- Conditional Disease Free Survival (CDFS)


Cancer Statistics

 Overall Survival:Length of time for a cancer patient is still alive after Dx. or Tx.


 Disease Free Survival: Length of time for a cancer patient survives without any sign or symptoms of that cancer.

Conditional DFS: The chance of surviving additional length of time for those who have already survived for certain period of time from the diagnosis (Example: CDFS3 = DFS(x+3)/DFS(x)

Cancer Statistics (Overall and Disease Free Survival)



Adrenocortical Carcinoma s/p Curative surgery (n=192) (Conditional Disease Free Survival)



New-onset DM after Renal Transplantation (NODAT)

- About 1/3 of non-diabetic kidney transplant recipients develop DM by 6 months posttransplantation
- Age, Obesity, African-American/Hispanic,
 Family Hx, impaired glucose tolerance
 Immunosupression, HLA mismatch, Sex Type of underlying renal disease.

New-onset DM after Renal Transplantation (NODAT)

One Year Survival: 98 % for non-NODAT 83 % for NODAT

Mean Survival: 11 years for non-NODAT
 8 years for NODAT

 Pretransplantation screeing is important; Life style modification, Management of cardiovascular risk factors such as hypertension and dyslipidemia

New-onset DM after Renal Transplantation (NODAT)

Study Findings

- Glycated hemoglobin (HbA1c) is a form of <u>hemoglobin</u> that is measured primarily to identify the three month average <u>plasma glucose concentration</u>
- HbA1c > 6.5 % diagnostic of DM (ADA)
- **HbA1c:** 5.7 % 6.4 % considered to be prediabetic (ADA)
- 1,499 patients of non-diabetic primary kidney transplant recipients' HbA1c values analyzed retrospectively in relation to PTDM.
- 395 recipients out of 1499 patients developed PTDM
- HbA1c, < 5.4 %:not associated with PTDM
- HbA1c, > 5.4 % was associated with PTDM (Hazard ratio of 1.85) well below current threshold for prediabetes

New-onset DM after Renal Transplantation (NODAT)

Study Findings

Univariate analysis Vs. Multivariate analysis

- What other risk factors (family Hx, obesity, race, sex and etc) were analyzed in addition to HbA1c?
- Were any other risk factors independently associated with PTDM ?
- What % of patients who had pre-transplant HbA1c between 5.4 % and 5.7 % developed PTDM ?
- What % of patients who had pre-transplant HbA1c > 5.7 % developed PTDM ?

Quality Measures Focused on Patient and Family Engagement in Oncology

- "Pay for Procedures" → "**Pay for Performance**"
- Affordable Care Act of 2010 include provision to develop the Hospital Value-Based Purchasing program.
- How to measure performance on quality of care ?
- Physician assessment vs. Patient self assessment or Other measures?
- Validity and Reliability
- CMS in 2014 established mortality outcome measures in acute myocardial infarction, pneumonia and heart failure.

Quality Measures Focused on Patient and Family Engagement in Oncology

- Dept. of Health and Human Services: Emphasizes that each person and family are engaged as partners in their care.
- Studies have shown patient engagement can lead to improved healthcare outcomes and reduced costs
- Alvalere assessed patient and family engagement measures related to oncology including patient education, care preference, and care planning.

Quality Measures Focused on Patient and Family Engagement in Oncology Study Findings

 Five oncology-specific measures related to person and family engagement studied.

Those are

Physician Quality Reporting System Record I
Electronic Health Record Incentive Programs
Three measures related to documenting end of life care: two related to care planning for pain and depression one related to patient education on treatment.

None of the studied measures were related to specific cancers(?) or cancer outcomes (?)

Conclusion: Standardized methodology for measuring engagement to be developed to improve quality of care in Oncology.